What is the primary purpose of this 10-Q filing for Bristol Myers Squibb?

This 10-Q filing provides Bristol Myers Squibb's (BMY) unaudited financial results and other relevant business information for the quarterly period ending September 29, 2025. It allows investors to assess the company's performance, financial health, and operational developments during this specific period.

Where can I find details about BMY's revenue and profitability in this filing?

Details regarding BMY's revenue, cost of goods sold, operating expenses, and net earnings can be found in the 'Consolidated Statements of Earnings and Comprehensive Income/(Loss)' and further elaborated in 'Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations'.

What are the key risks that Bristol Myers Squibb faces, according to this report?

The 'Item 1A. Risk Factors' section of this 10-Q filing will outline the significant risks and uncertainties that could materially affect BMY's business, financial condition, or results of operations. Investors should review this section carefully to understand potential challenges.

How is Bristol Myers Squibb managing its cash and financial resources?

The 'Consolidated Statements of Cash Flows' will detail the company's cash inflows and outflows from operating, investing, and financing activities. 'Item 2. Management’s Discussion and Analysis' will provide further qualitative and quantitative insights into the company's financial condition, liquidity, and capital resources.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q3 FY2025

Summary

Bristol Myers Squibb (BMY) reported its financial results for the period ending September 29, 2025. The company's third-quarter performance indicates a stable financial position, with key metrics expected to be closely scrutinized by investors in light of ongoing market dynamics and product pipeline developments. Management's Discussion and Analysis will provide crucial insights into revenue drivers, operating expenses, and the company's strategic outlook, particularly concerning R&D investments and potential commercial successes. Investors should pay close attention to the company's revenue generation across its key therapeutic areas, the impact of any patent expirations or new drug approvals, and the company's cash flow from operations. The balance sheet details will reveal the company's debt levels and liquidity position, while the cash flow statement will illustrate how the company is investing in its future growth and returning capital to shareholders. Understanding these elements is vital for assessing BMY's ongoing value and future prospects.

Financial Highlights

55 data points

Beta

Revenue

$12.22B

0.7% Gross Margin

Net Income

$2.20B

0.2% Net Margin

EPS (Diluted)

$1.08

Total Assets

$96.89B

Cash & Equivalents

$15.73B

Free Cash Flow

$5.99B

Financial Statements

Beta

Revenue	$12.22B
Cost of Revenue	$3.44B
Gross Profit	$8.79B
R&D Expenses	$2.53B
SG&A Expenses	$1.79B
Operating Expenses	$9.11B
Net Income	$2.20B
EPS (Basic)	$1.08
EPS (Diluted)	$1.08
Shares Outstanding (Basic)	2.04B
Shares Outstanding (Diluted)	2.04B

Key Highlights

1The 10-Q filing covers the financial performance of Bristol Myers Squibb (BMY) for the period ending September 29, 2025.
2Key financial statements, including Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, are provided.
3Management's Discussion and Analysis (MD&A) offers commentary on the company's financial condition and results of operations.
4The report details legal proceedings and provides an update on risk factors that could impact the business.
5Information on unregistered sales of equity securities and the use of proceeds is included.
6Exhibits are listed, which may contain further supporting documentation for the financial disclosures.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions